Venture Capital Executive Sells Hundreds of Billions in Rare Disease Drug Shares

Dyne Therapeutics, Inc. (Nasdaq: DYN), a developer of rare-disease therapies, disclosed that its reporting person, Jason P. Rose, sold shares held by several Atlas Venture–affiliated funds on the open market under a pre-arranged Rule 10b5-1 trading plan from April 20 to 22, 2026. During that period, the funds sold several hundred thousand shares at roughly $20 per share, generating gross proceeds of about $15 million (approximately KRW 20 billion). Even after this sale, the Atlas-affiliated funds connected to Rose continue to hold an indirect stake of several million Dyne Therapeutics shares on a fully diluted basis.

Dyne Therapeutics also announced that it will present data from its key neuromuscular disease pipeline—covering Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and Pompe disease—at the 2026 Muscular Dystrophy Association (MDA) Scientific Conference in February, highlighting its clinical development progress.

In March, the company reported full-year 2025 results, noting a net loss of $446 million but a cash position exceeding $1 billion. Dyne said it plans to submit accelerated approval applications for core assets such as DYNE-251 and aims for a commercial launch in 2027.

Headquartered in Waltham, Massachusetts, Dyne Therapeutics is a clinical-stage biotech focused on improving function in patients with hereditary neuromuscular diseases. Using its proprietary FORCE platform to deliver targeted nucleic acid and enzyme therapies to muscle and central nervous system tissues, the company is listed on Nasdaq under the ticker DYN.